UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia® (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19.

"UCB is committed to supporting ongoing research that generates new clinical insights into our immunological treatments," said Professor Dr. Iris Loew Friedrich, Chief Medical Officer and Executive Vice President, UCB. "Research on Cimzia after its initial US approval in 2008 has spanned seven years and these latest results contribute to the body of evidence supporting its important role as a treatment for Crohn's disease."

In the U.S., CIMZIA® is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. See important safety information including risk of serious bacterial, viral and fungal infections and tuberculosis below.

Posters on Cimzia for Crohn's Disease at DDW

  • The Effect of Anti-Drug Antibodies on Adverse Events Profile in Patients with Crohn's Disease Treated with Certolizumab Pegol: Results of an Integrated Safety Analysis from Clinical Trials
    • Date and Time: Saturday, May 16, 9:30 AM
    • Location: HALL C (WCC)
    • Poster Number: Sa1120
  • Serious Infectious Complications in Patients Treated with Certolizumab Pegol: A Pooled Analysis of 15 Crohn's Disease Global Clinical Trials
    • Date and Time: Saturday, May 16, 9:30 AM
    • Location: HALL C (WCC)
    • Poster Number: Sa1135
  • Safety of Certolizumab Pegol in 2570 Crohn's Disease Patients with 4378 Patients Years at Risk: Integrated Data from the Global Clinical Program
    • Date and Time: Saturday, May 16, 9:30 AM
    • Location: HALL C (WCC)
    • Poster Number: Sa1139
  • Evaluation of Real-World Risk of Malignancies in Crohn's Disease Patients Treated with Certolizumab Pegol: Results from the SECURE Registry
    • Date and Time: Saturday, May 16, 9:30 AM
    • Location: HALL C (WCC)
    • Poster Number: Sa1136
  • Remission Rates In Crohn's Disease Patients Treated With A Re-Induction Regimen Of Certolizumab Pegol After Experiencing Disease Exacerbation: 7 Year Results From The PRECiSE 4 Study
    • Date and Time: Saturday, May 16, 9:30 AM
    • Location: HALL C (WCC)
    • Poster Number: Sa1219
  • Early Remission Status as a Predictor of Long-Term Outcome in Crohn's Disease Patients Treated With Certolizumab Pegol: Results of an Analysis from the PRECiSE 3 Study
    • Date and Time: Saturday, May 16, 9:30 AM
    • Location: HALL C (WCC)
    • Poster Number: Sa1190

Poster on Cimzia and Pregnancy

  • Pregnancy Outcomes after Exposure to Certolizumab Pegol: Updated Results from Safety Surveillance
    • Date and Time: Tuesday, May 19, 9:30 AM
    • Location: HALL C (WCC)
    • Poster Number: Tu1320
Source:

UCB

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Cell factors decide if a cancer grows or dies, says new study